John Glenn
Known title: Chief Financial OfficerCIK: 0001253497
Associated companies
Transaction History
| IRMD | ▲ Buy | Option Exercise | 5,796 | — | 6/20/2026 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 2,319 | $214K | 6/20/2026 | View on chart |
| IRMD | ▼ Sell | Open Market | 14,468 | $1.4M | 12/11/2025 | View on chart |
| IRMD | ▼ Sell | Open Market | 532 | $52K | 12/11/2025 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 1,812 | — | 12/11/2025 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 714 | $70K | 12/11/2025 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 10,504 | — | 12/7/2025 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 3,383 | $320K | 12/7/2025 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 21,008 | — | 12/7/2025 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 8,267 | $782K | 12/7/2025 | View on chart |
| IRMD | ▼ Sell | Open Market | 10,651 | $900K | 11/10/2025 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 5,796 | — | 6/20/2025 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 1,412 | $82K | 6/20/2025 | View on chart |
| IRMD | ▼ Sell | Open Market | 2,500 | $135K | 12/2/2024 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 5,796 | — | 6/20/2024 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 1,412 | $60K | 6/20/2024 | View on chart |
| IRMD | ▲ Buy | Option Exercise | 5,795 | — | 6/20/2023 | View on chart |
| IRMD | ▼ Sell | Tax Withholding | 1,412 | $68K | 6/20/2023 | View on chart |
| IRMD | ▲ Buy | Grant | 2,500 | $72K | 12/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
iRadimed Gets Needham Hold Rating and Conference Participation
Needham initiated coverage on iRadimed with a Hold rating, while the company announced it will speak at the ROTH Healthcare Opportunities Conference. These developments add analyst visibility to the stock, which is currently trading near its 52-week high. The new coverage provides a fresh perspective on the company's position in the medical imaging sector.
iRadimed Gets Needham Hold Rating and Conference Participation. Needham initiated coverage on iRadimed with a Hold rating, while the company announced it will speak at the ROTH Healthcare Opportunities Conference. These developments add analyst visibility to the stock, which is currently trading near its 52-week high. The new coverage provides a fresh perspective on the company's position in the medical imaging sector.